Chronic wounds like diabetic foot ulcers are a serious global health problem. These non-healing wounds affect millions and lead to high treatment costs, amputations, and even death. Aurealis Therapeutics has developed AUP-16, an innovative, genetically engineered lactic acid bacterium designed to actively treat chronic wounds.
AUP-16 is a first-in-class 4-in-1 biological drug. It combines three therapeutic human proteins (IL-4, CSF-1, and FGF2) with the immune-stimulating properties of the live bacterium itself. Together, they act on the full wound healing cascade, from restarting the immune response, to shifting inflammation into a regenerative mode, and stimulating new tissue growth and skin remodeling.
Here’s how it works:
-
Step 1: AUP-16 reboots the chronic wound by activating immune cells and converting chronic inflammation into acute inflammation.
-
Step 2: It shifts the local environment from hostile to healing by changing the mix of cytokines and growth factors.
-
Step 3: The growth factors promote fibroblast proliferation, new blood vessels, and skin regeneration.
-
Step 4: Finally, the skin is restored and strengthened for long-term healing.
Non-clinical studies show strong efficacy and safety, and clinical trials in diabetic foot ulcer patients are ongoing.
Learn more at aurealistherapeutics.com
